MA35345B1 - Proteines de liaisons a un antigene ayant une liaison accrue a fcrn - Google Patents
Proteines de liaisons a un antigene ayant une liaison accrue a fcrnInfo
- Publication number
- MA35345B1 MA35345B1 MA36748A MA36748A MA35345B1 MA 35345 B1 MA35345 B1 MA 35345B1 MA 36748 A MA36748 A MA 36748A MA 36748 A MA36748 A MA 36748A MA 35345 B1 MA35345 B1 MA 35345B1
- Authority
- MA
- Morocco
- Prior art keywords
- binding
- proteins
- fcrn
- antigen
- increased
- Prior art date
Links
- 101150050927 Fcgrt gene Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 229960002964 adalimumab Drugs 0.000 abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des protéines de liaison à un antigène qui se lient spécifiquement au tnf-alpha. Par exemple, l'invention concerne de nouveaux variants d'anticorps anti-tnf, tels que adalimumab, qui présentent une liaison accrue au récepteur fcrn ou une demi-vie prolongée en comparaison à adalimumab. L'invention concerne également des compositions comprenant les protéines de liaison à un antigène et des utilisations de telles compositions dans le traitement de troubles et d'une maladie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1112429.4A GB201112429D0 (en) | 2011-07-19 | 2011-07-19 | Antigen-binding proteins with increased FcRn binding |
PCT/EP2012/064129 WO2013011076A2 (fr) | 2011-07-19 | 2012-07-19 | Protéines de liaison à un antigène ayant une liaison accrue à fcrn |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35345B1 true MA35345B1 (fr) | 2014-08-01 |
Family
ID=44586854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36748A MA35345B1 (fr) | 2011-07-19 | 2014-02-12 | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn |
Country Status (21)
Country | Link |
---|---|
US (1) | US20130243764A1 (fr) |
EP (2) | EP2734548B1 (fr) |
JP (1) | JP2014524748A (fr) |
KR (1) | KR20140054085A (fr) |
CN (1) | CN103748110A (fr) |
AU (1) | AU2012285786B2 (fr) |
BR (1) | BR112014000341A2 (fr) |
CA (1) | CA2841105A1 (fr) |
CL (1) | CL2014000134A1 (fr) |
CO (1) | CO6862106A2 (fr) |
CR (1) | CR20140029A (fr) |
DO (1) | DOP2014000007A (fr) |
EA (1) | EA201391789A1 (fr) |
ES (1) | ES2600854T3 (fr) |
GB (1) | GB201112429D0 (fr) |
MA (1) | MA35345B1 (fr) |
MX (1) | MX2014000739A (fr) |
PE (1) | PE20141660A1 (fr) |
SG (1) | SG10201601154QA (fr) |
WO (1) | WO2013011076A2 (fr) |
ZA (1) | ZA201400062B (fr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2868614A1 (fr) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methodes pour administrer des anticorps anti-tnf.alpha. |
UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
EP2822591B1 (fr) | 2012-03-07 | 2018-05-02 | Cadila Healthcare Limited | Formulations pharmaceutiques d'anticorps anti-tnf-alpha |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158275A1 (fr) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Procédés de culture cellulaire pour réduire des espèces acides |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
US20150150982A1 (en) * | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
DK2892550T3 (da) | 2012-09-07 | 2020-03-30 | Coherus Biosciences Inc | Stabile vandige formuleringer af adalimumab |
FR2999431B1 (fr) * | 2012-12-17 | 2016-03-18 | Lfb Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
CA2894225A1 (fr) * | 2012-12-17 | 2014-06-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
KR20150110659A (ko) * | 2013-01-24 | 2015-10-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tnf-알파 항원-결합 단백질 |
CA2905010A1 (fr) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Anticorps humains qui se lient au tnf-alpha et leurs procedes de preparation |
EP2836515A1 (fr) * | 2013-03-14 | 2015-02-18 | AbbVie Inc. | Compositions d'espèces faiblement acides et leurs procédés de production et d'utilisation |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014159579A1 (fr) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation |
RU2662558C2 (ru) * | 2013-07-19 | 2018-07-26 | Хексаль Аг | Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства |
EP3052640A2 (fr) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes |
WO2015057910A1 (fr) | 2013-10-16 | 2015-04-23 | Oncobiologics, Inc. | Formulations de tampon pour stabilité d'anticorps améliorée |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
WO2015073884A2 (fr) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Compositions de protéines de liaison génétiquement glycomodifiées |
ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
EP2946767B1 (fr) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Composition pharmaceutique liquide |
PT2946765T (pt) | 2014-05-23 | 2016-11-10 | Ares Trading Sa | Composição farmacêutica líquida |
PE20171139A1 (es) | 2014-09-03 | 2017-08-09 | Boehringer Ingelheim Int | Compuesto dirigido a il-23a y tnf-alfa y sus usos |
HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
WO2016118707A1 (fr) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation de variants de charge dans une composition d'anticorps monoclonaux |
UY36542A (es) * | 2015-01-28 | 2016-08-31 | Mabxience S A | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa |
WO2016189491A1 (fr) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Nouvelle formulation |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
EP3395835B1 (fr) * | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Anticorps présentant une activité accrue et son procédé de modification |
MX2018009341A (es) | 2016-02-03 | 2019-05-15 | Oncobiologics Inc | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
CN116239693A (zh) | 2016-03-14 | 2023-06-09 | 奥斯陆大学 | 具有改变的FcRn结合的工程化免疫球蛋白 |
WO2017184880A1 (fr) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | Procédé de remplissage d'un récipient sans espace libre |
CN110072887A (zh) | 2016-08-02 | 2019-07-30 | 威特拉公司 | 工程化多肽及其应用 |
TWI778985B (zh) * | 2016-10-20 | 2022-10-01 | 法商賽諾菲公司 | 抗chikv抗體及其用途 |
ES2933808T3 (es) * | 2017-01-11 | 2023-02-14 | Celltrion Inc | Fórmula líquida estable |
EP3569615A4 (fr) * | 2017-01-13 | 2020-07-29 | Hanx Biopharmaceutics, Inc | Procédé pour améliorer l'affinité de liaison d'un anticorps igg vis-à-vis du fcrn et prolonger la demi-vie sérique de celui-ci |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
EP3372242A1 (fr) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Composition pharmaceutique liquide |
EP3372241A1 (fr) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Composition pharmaceutique liquide |
CN111032688A (zh) * | 2017-08-11 | 2020-04-17 | 研究发展基金会 | 用于延长的血清半衰期的工程化抗体fc变体 |
KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
WO2019147973A1 (fr) * | 2018-01-26 | 2019-08-01 | Genzyme Corporation | Variants fc présentant une liaison améliorée à fcrn et demi-vie prolongée |
WO2020178822A1 (fr) * | 2019-03-05 | 2020-09-10 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Oiseaux à édition de génome |
AU2022401939A1 (en) * | 2021-11-30 | 2024-05-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-sost antibody pharmaceutical composition and use thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
RO123028B1 (ro) * | 1996-02-09 | 2010-07-30 | Abbott Laboratories (Bermuda) Ltd. | Anticorpi umani, care leagă tnf alpha uman |
CA2249195A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
JP4336498B2 (ja) * | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
ES2523666T3 (es) * | 2005-05-31 | 2014-11-28 | Board Of Regents, The University Of Texas System | Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos |
US8034906B2 (en) * | 2006-10-27 | 2011-10-11 | Abbott Biotechnology Ltd. | Crystalline anti-hTNFalpha antibodies |
EP2527367A1 (fr) | 2007-08-20 | 2012-11-28 | Glaxo Group Limited | Procédé de production |
AU2008345242B2 (en) * | 2007-10-31 | 2014-02-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101710472B1 (ko) * | 2007-11-30 | 2017-02-27 | 글락소 그룹 리미티드 | 항원-결합 작제물 |
AU2008334099B2 (en) * | 2007-11-30 | 2014-07-24 | Abbvie Biotechnology Ltd. | Protein formulations and methods of making same |
WO2009073805A2 (fr) * | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Anticorps thérapeutiques aglycosylés et séquences nucléotidiques codant les anticorps thérapeutiques |
JP5570998B2 (ja) * | 2007-12-31 | 2014-08-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | TNFαに対する抗体 |
FR2934599B1 (fr) | 2008-07-29 | 2012-12-21 | Arkema France | Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations |
US9393304B2 (en) * | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
CA2753287A1 (fr) * | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Constructions de liaison d'antigene |
SG173705A1 (en) * | 2009-03-05 | 2011-09-29 | Abbott Lab | Il-17 binding proteins |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
US20120076787A1 (en) * | 2009-05-28 | 2012-03-29 | Peter Adamson | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye |
WO2011074965A1 (fr) * | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Méthodes et moyens pour contrer une activité d'un domaine fc |
EP2637690B1 (fr) | 2010-11-11 | 2016-09-21 | AbbVie Biotechnology Ltd | FORMULATION LIQUIDE D'ANTICORPS ANTI-TNFalpha HAUTEMENT CONCENTRÉE |
-
2011
- 2011-07-19 GB GBGB1112429.4A patent/GB201112429D0/en not_active Ceased
-
2012
- 2012-07-19 ES ES12738101.0T patent/ES2600854T3/es active Active
- 2012-07-19 KR KR1020147004161A patent/KR20140054085A/ko not_active Application Discontinuation
- 2012-07-19 EP EP12738101.0A patent/EP2734548B1/fr active Active
- 2012-07-19 US US13/988,400 patent/US20130243764A1/en not_active Abandoned
- 2012-07-19 BR BR112014000341A patent/BR112014000341A2/pt not_active IP Right Cessation
- 2012-07-19 JP JP2014520658A patent/JP2014524748A/ja active Pending
- 2012-07-19 EP EP15197750.1A patent/EP3009450A1/fr not_active Withdrawn
- 2012-07-19 SG SG10201601154QA patent/SG10201601154QA/en unknown
- 2012-07-19 CN CN201280034887.5A patent/CN103748110A/zh active Pending
- 2012-07-19 EA EA201391789A patent/EA201391789A1/ru unknown
- 2012-07-19 AU AU2012285786A patent/AU2012285786B2/en not_active Ceased
- 2012-07-19 MX MX2014000739A patent/MX2014000739A/es unknown
- 2012-07-19 CA CA2841105A patent/CA2841105A1/fr not_active Abandoned
- 2012-07-19 PE PE2014000086A patent/PE20141660A1/es not_active Application Discontinuation
- 2012-07-19 WO PCT/EP2012/064129 patent/WO2013011076A2/fr active Application Filing
-
2014
- 2014-01-06 ZA ZA2014/00062A patent/ZA201400062B/en unknown
- 2014-01-17 CL CL2014000134A patent/CL2014000134A1/es unknown
- 2014-01-17 DO DO2014000007A patent/DOP2014000007A/es unknown
- 2014-01-20 CR CR20140029A patent/CR20140029A/es unknown
- 2014-01-21 CO CO14011137A patent/CO6862106A2/es not_active Application Discontinuation
- 2014-02-12 MA MA36748A patent/MA35345B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140054085A (ko) | 2014-05-08 |
CA2841105A1 (fr) | 2013-01-24 |
ES2600854T3 (es) | 2017-02-13 |
MX2014000739A (es) | 2014-02-19 |
WO2013011076A2 (fr) | 2013-01-24 |
GB201112429D0 (en) | 2011-08-31 |
US20130243764A1 (en) | 2013-09-19 |
BR112014000341A2 (pt) | 2017-02-14 |
WO2013011076A3 (fr) | 2013-04-04 |
AU2012285786B2 (en) | 2016-05-12 |
PE20141660A1 (es) | 2014-11-21 |
ZA201400062B (en) | 2017-08-30 |
CN103748110A (zh) | 2014-04-23 |
AU2012285786A1 (en) | 2014-02-06 |
DOP2014000007A (es) | 2014-04-30 |
CO6862106A2 (es) | 2014-02-10 |
EP2734548B1 (fr) | 2016-08-17 |
EA201391789A1 (ru) | 2014-06-30 |
EP2734548A2 (fr) | 2014-05-28 |
SG10201601154QA (en) | 2016-03-30 |
EP3009450A1 (fr) | 2016-04-20 |
CR20140029A (es) | 2014-03-05 |
JP2014524748A (ja) | 2014-09-25 |
NZ618897A (en) | 2016-02-26 |
CL2014000134A1 (es) | 2014-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
MA34927B1 (fr) | Anticorps anti-cea | |
MA29374B1 (fr) | Anticorps anti-ccr5 et leurs utilisations | |
MA35428B1 (fr) | Proteines et peptides podifies | |
MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
MA35174B1 (fr) | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
MA29279B1 (fr) | Molecules de liaison d'antigenes se liant au recepteur egfr, vecteurs codant pour ces molecules et leurs applications | |
TNSN07398A1 (fr) | Anticorps contre la p-cadherine | |
BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
CA2868907C (fr) | Anticorps anti-hla-b*27 et leurs utilisations | |
MA29226B1 (fr) | Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations | |
MA34527B1 (fr) | Anticorps contre la metalloproteinase de matrice 9 | |
MXPA06012601A (es) | Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos. | |
UA108066C2 (uk) | Білки, що зв'язуються з cgrp-рецепторами людини | |
MA33387B1 (fr) | Polypeptides et procede de traitement | |
WO2014114651A9 (fr) | Protéines de liaison à l'antigène tnf-alpha | |
MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
EA200870274A1 (ru) | ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn | |
MA31838B1 (fr) | Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations | |
MA34461B1 (fr) | Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations | |
MA33757B1 (fr) | Protéines de liaison à l'antigène de l'il-23 humaine | |
MA30353B1 (fr) | Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes. | |
MA38161A1 (fr) | Anticorps anti-bmp-6 |